Spectrodensitometric determination of Rivastigmine (cas 123441-03-2) after vortex assisted magnetic solid phase extraction
-
Add time:07/20/2019 Source:sciencedirect.com
A highly sensitive and cost-effective HPTLC method was developed for the determination of Rivastigmine (cas 123441-03-2) hydrogen tartarate (RIV) in bulk and capsules. Moreover, magnetic solid phase extraction procedure (MSPE) was performed for analysis of RIV in human plasma to preconcentrate RIV and decrease interference from plasma constituents. The magnetic nanoparticles (MNPs) were prepared by co-precipitation process and characterized by scanning electron microscope (SEM), Fourier transform infrared spectroscopy (FTIR), powdered X-ray diffraction (PXRD) and dynamic light scattering (DLS). These prepared MNPs have shown high extraction efficiency and all parameters affecting the adsorption of RIV on the MNPs were fully investigated. The method was validated according to FDA bio-analytical guidelines and was found to be linear over the range of 30.2–648 ng/spot. The LLOQ and LOD were 26.2 and 8.6 ng/spot, respectively.
We also recommend Trading Suppliers and Manufacturers of Rivastigmine (cas 123441-03-2). Pls Click Website Link as below: cas 123441-03-2 suppliers
Prev:Persistence and adherence to Rivastigmine (cas 123441-03-2) in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan
Next:Enhancement of oral bioavailability of Rivastigmine (cas 123441-03-2) with quercetin nanoparticles by inhibiting CYP3A4 and esterases) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Controlled delivery of Rivastigmine (cas 123441-03-2) using transdermal patch for effective management of alzheimer's disease07/24/2019
- Paroxetine and Rivastigmine (cas 123441-03-2) mitigates adjuvant-induced rheumatoid arthritis in rats: Impact on oxidative stress, apoptosis and RANKL/OPG signals07/23/2019
- Enhancement of oral bioavailability of Rivastigmine (cas 123441-03-2) with quercetin nanoparticles by inhibiting CYP3A4 and esterases07/22/2019
- Persistence and adherence to Rivastigmine (cas 123441-03-2) in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan07/21/2019